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Abstract The relevance of MDR-1 gene expression to the 
multidrug resistance phenotype was investigated. Drug-resistant 
cells, KB-V1 and MCF7/ADR, constantly expressed mRNA of 
the MDR-1 gene and were more resistant to vinblastine and 
adriamycin than drug-sensitive cells, KB-3-1 and MCF7. The 
drug efflux rate of KB-V1 was the same as KB-3-1 although the 
MDR-1 gene was expressed in only the resistant cell. The higher 
intracellular drug concentration of KB-3-1 than KB-V1 was due 
to the large drug influx. In the case of MCF7 and MCF7/ADR, 
the influx and efflux of the drug had nearly the same pattern and 
drug efflux was not affected by verapamil. The amount of ATP, 
cofactor of drug pumping activity of P-glycoprotein, was not 
changed by the resistance. These observations suggested that 
drug efflux mediated by MDR-1 gene expression was not a major 
determining factor of drug resistance in the present cell systems, 
and that the drug resistance could be derived from the change in 
drug uptake and other mechanisms. 
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1. Introduction 
The majority of the acquired resistances of cancer cells to 
anticancer agents is considered to be related with M D R gene 
expression and the presence of P-glycoprotein (P-gp) which 
pumps out the intracellular drug [1]. However, recent studies 
have suggested that there are some exceptions. In the highly 
drug-resistant KB-A1 and KB-A10 cell lines, the level of drug 
resistance is not proport ional to the expression of P-gp or to 
other common factors such as protein kinase C (PKC) activ-
ity, glutathione-5-transferase and topoisomerase II, which are 
thought to participate in drug insensitivity [2]. A multidrug-
resistant HOB1/ADR lymphoma cell line showed a lack of 
reduced accumulation and of enhanced efflux of adriamycin 
[3]. Changes in subcellular drug distribution and cellular ac-
cumulation were observed in adriamycin-resistant sublines of 
SW-1573 lung cancer and M C F 7 breast cancer cells [4]. It was 
found that multidrug resistance-associated protein (MRP) and 
M R P m R N A were expressed in the adriamycin-resistant KB 
cells but not in the parental KB-3-1 cells [5]. Accordingly, it 
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could be assumed that drug resistances were mediated by 
many kinds of molecular mechanisms. 
In the present study, we tried to find unique cases, which 
expressed M D R gene in the resistant variant but did not par-
ticipate in the resistance. Two kinds of resistant and parental 
cells were selected and the cellular drug kinetics were exam-
ined. It was found that these cellular models could suggest the 
unique mechanisms of drug resistance. 
2. Materials and methods 
2.1. Chemicals 
All chemicals, including adriamycin, vinblastine, and rhodamine 
123, were purchased from Sigma (St. Louis, MO, USA). RPM1 
1640 medium and Hanks' balanced salt solution were purchased 
from Gibco BRL (Grand Island, NY, USA). 
2.2. Cell lines 
Human cancer cells (MCF7, MCF7/ADR, KB-3-1 and KB-V1) 
were cultured in RPMI 1640 medium containing 10% fetal calf serum 
(FCS, R10) at 37°C in a humidified atmosphere of 5% C0 2 . For 
consistent MDR-1 gene expression, MCF7/ADR and KB-V1 cells 
were maintained in the presence of adriamycin (ADR, 0.1 ug/ml) 
and vinblastine (VBL, 0.1 mM), respectively. 
2.3. Analysis of MDR-1 gene expression 
The level of MDR-1 gene was determined by a modification of 
previous methods [6,7]. Total cellular RNA was isolated by using 
the Ultraspec-11 RNA isolation system (Biotecx Lab. Inc., Houston, 
TX). cDNA was synthesized with 40 ng of total cellular RNA by 
using the GeneAmp RNA PCR kit (Perkin Elmer, Branchburg, 
NJ). Quantitative PCR was carried out with cDNA and 2.5 units of 
AmpliTaq DNA polymerase and human MDR-1 specific primer [8]. 
For the quantification of mRNA of MDR-1, mRNA of GAPDH was 
also amplified under the same conditions [9]. PCR products were 
separated on 3% agarose gel, followed by staining with ethidium bro-
mide. MDR-1 mRNA levels for each cell line were evaluated by the 
densitometric scanning method using Molecular Analyst Software 
(Bio-Rad Lab., Hercules, CA) and were expressed by the relative ratio 
to mRNA levels for GAPDH. 
2.4. Chemosensitivity 
Chemosensitivity was performed by a modification of previous 
methods [10,11]. Cells were incubated in RPMI 1640 medium contain-
ing 5% FCS (R5) for 24 h and ADR (3-0.03 ug/ml) or VBL (10-0.1 
Ug/ml) was added to the medium. After further incubation for 48 h, 
cells were fixed with 50% (w/v) trichloroacetic acid (TCA) solution at 
4°C for 1 h. After washing with tap water followed by drying in air, 
TCA-fixed cells were stained with 0.4% sulforhodamine B (SRB) dis-
solved in 1% acetic acid. After staining, the unbound dye was washed 
out with 1% acetic acid. To each well of the dried plate, 100 ul Tris 
base (10 mM, pH 10.5) was added. Optical density (OD) was meas-
ured with a microtiter plate reader (Molecular Devices, Model Emax, 
Menlo Park, CA) at 540 nm. 
2.5. Determination of rhodamine 123 uptake and release 
Cells (5X104 cells) were diluted in R10 and inoculated into each 
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well of 24-well microplates. Cells were incubated overnight at 37°C in 
an atmosphere of 5% CO2 and then washed two times with warm R5. 
Rhodamine 123 (R-123) uptake, the intracellular concentration of R-
123, was determined at the designated time after addition of R-123 (1 
Hg/ml) and washed six times with cold R5. For R-123 release experi-
ments, cells were incubated for the designated time in R5 containing 
R-123 and washed four times with cold R5. Then, the medium was 
changed to 37°C R5 without R-123 and incubated for the designated 
time and washed with cold R5. Intracellular R-123 was extracted 
twice with 0.2 ml n-butanol and the fluorescence intensity was meas-
ured with a Luminescence Spectrometer (Model LS50B, Perkin Elmer, 
UK) at an excitation wavelength of 518 nm and emission wavelength 
of 532 nm. The amount of R-123 was calculated by a standard curve 
of R-123 [12]. In the present experiment, R123 did not affect cell 
viability and morphology. 
2.6. Effect of verapamil on R-123 and ADR release 
Cells were incubated in Hanks' balanced salt solution (HBSS) con-
taining either R-123 (1 ug/ml) [12] or ADR (10 ug/ml) for 15 min and 
washed four times with cold HBSS. The concentration of adriamycin 
was determined by the previous experiment on the dose-dependent 
uptake of adriamycin at a concentration which was non-cytotoxic. 
The medium was changed to 37°C HBSS with or without 5 uM 
verapamil and incubated for the designated time and washed with 
cold HBSS. Verapamil did not affect cell viability determined by try-
pan blue dye uptake. Intracellular R-123 was determined as described 
above. Intracellular ADR was extracted with 1 ml of 0.3 N HCl-50% 
ethanol [13] and the amount was determined by high-performance 
liquid chromatography (HPLC). The chromatographic separations 
were accomplished on a Waters Millipore model 510 liquid chromato-
graph (Millipore, Mariborough, MA) equipped with Lichrosorb RP-
18 10 11m column of 10 urn particle size (Waters Assoc, Waltham, 
MA). An isocratic solvent system (mobile phase) was used consisting 
of 0.05 M NaH2P04/methanol (70 : 30, v/v). The flow rate was 1.6 
ml/min. Fluorescence was measured with a Model Waters 470 liquid 
chromatography fluorometer (Millipore). The excitation wavelength 
was 470 nm and the emission wavelength was 585 nm [13]. 
2.7. Determination of intracellular A TP concentration 
After treatment of R-123 for 5 or 20 min, the amount of intra-
cellular ATP was determined [14]. Intracellular ATP was directly ex-
tracted and quantified by using the ATP bioluminescence assay kit 
(Boehringer Mannheim, GmbH, Germany). ATP bioluminescence 
was measured with a Luminescence Spectrometer (Perkin Elmer) at 
an emission wavelength of 562 nm. The concentration of ATP was 
calculated by a standard curve of ATP (10~5 M-10- 1 2 M). 
3. Results 
3.1. The expression of MDR-1 gene and chemosensitivity 
Drug resistance phenotype was determined by M D R - 1 gene 
expression and chemosensitivity. The RT-PCR analysis 
showed that the sensitive cells, M C F 7 and KB-3-1, did not 
produce m R N A of the M D R - 1 gene but the resistant variants, 
M C F 7 / A D R and KB-V1, expressed the M D R - 1 gene (Fig. 
1A). The ratios of the M D R - 1 m R N A to G A P D H m R N A 
in M C F 7 / A D R and KB-V1 were calculated to 0.768 and 
1.212, respectively (Fig. IB). 
The resistance of M C F 7 / A D R and KB-V1 to anticancer 
agents was also shown in the determination of chemosensitiv-
ity. Vinblastine suppressed the growth of KB-3-1 at a low 
concentration of 0.1 (j.g/ml but the same extent of cytotoxicity 
was observed only at concentrations higher than 3 |J.g/ml in 
KB-V1. In the case of M C F 7 and M C F 7 / A D R , a significant 
difference of growth was observed at concentrations higher 
than 0.1 |Xg/ml of adriamycin (Fig. 2A). The calculated GI50 
is shown in Fig. 2B. F r o m the results, it was certain that the 
present resistant cells constantly expressed m R N A of M D R - 1 
and were more resistant than their parental cells. 
3.2. Uptake and release of R-123 
The rate of drug uptake and release was measured by using 
R-123. KB-3-1 had a higher uptake rate than KB-V1 for 30 
min exposure, but the release rate of the two cell lines was the 
same (Fig. 3A). M C F 7 had the same uptake rate of R-123 
B 




Fig. 1. RT-PCR analysis of MDR-1 gene expression. Total RNA (40 ng) was amplified with the primers of MDR-1 (lower) and GAPDH 
(upper) (A). The product of RT-PCR was detected with agarose gel electrophoresis. Relative levels of MDR-1 and GAPDH mRNA were esti-
mated as described in Section 2. The ratio of MDR-1 to GAPDH is listed in (B). 
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Fig. 2. Chemosensitivity of sensitive, KB-3-1 and MCF7, and resistant cells, KB-Vl and MCF7/ADR. Chemosensitivity of these cells was de-
termined by sulforhodamine B (SRB) assay (A). Adriamycin was added from 0.3 to 3 |J,g/ml and vinblastine was added from 0.1 to 10 |xg/ml. 
50% growth inhibition (GI50) was calculated and listed in (B). The data present the mean values ± standard deviation of three independent ex-
periments which were done in six separate analyses. 
with MCF7/ADR, and showed a slightly higher release rate of 
R-123 than MCF7/ADR (Fig. 3B). 
Time-dependent uptake and release of R-123 were deter-
mined every 15 min. Fig. 4A shows that intracellular R-123 
concentration in KB-3-1 steadily increases up to 60 min but 
that of KB-Vl slowly increases up to 30 min and then slowly 
decreases up to 60 min. Even though the intracellular concen-
trations of R-123 in KB-3-1 and KB-Vl were different at each 
time point, the release rate of R-123 was nearly the same. 
These results possibly reflect that MDR-1 gene expression 
was not related with the intracellular drug accumulation. 
The same experiment was done in MCF7 and MCF7/ADR 
and the result is depicted in Fig. 4B. These two cell lines had 
almost the same rate of uptake and release of R-123. Uptake 
and release of adriamycin in the resistant cells were also the 
same as in the sensitive cells (unpublished results). In these 
cells, MDR-1 gene expression did not match with the drug 
uptake and release. 
3.3. Effect of verapamil on drug release and quantification of 
ATP 
To confirm whether P-gp, product of MDR-1 gene, is in-
volved in the determination of intracellular drug accumula-
tion, verapamil (VP) was exposed to MCF7 and MCF7/ 
ADR in the drug release experiment. Verapamil did not 
change the release rate of R-123 or ADR in either cell (Fig. 
5). These results supported the previous results that P-gp was 
not involved in controlling the intracellular drug concentra-
tion of MCF7 and MCF7/ADR. 
Next, the amount of ATP was determined to examine 
whether depletion of ATP affected the release and uptake of 
R-123. Fig. 6 shows that the amount of ATP, the cofactor of 
drug pumping activity of P-gp, was nearly the same between 
the resistant and sensitive cells, suggesting that P-gp was not 
functionally affected. 
4. Discussion 
KB-Vl cells showed the over-expression of MDR-1 gene, 
which is known as a major factor in changing intracellular 
drug concentration, and also showed a high resistance to vin-
blastine when compared with KB-3-1 cells. In spite of the 
difference in MDR-1 mRNA expression between sensitive 
and resistant cells, the decreased intracellular drug concentra-
tion in KB-Vl was mediated by the uptake rate but not the 
release rate. As shown in Fig. 4A, the intracellular R-123 
concentration of KB-3-1 at 60 min after R-123 exposure 
was 592% of KB-Vl, but the release rates of the two cells 
were almost the same. Accordingly, the low intracellular 
drug accumulation of KB-Vl might be mediated by a low 
drug influx but not a high drug efflux mediated by P-gp. In 
the present system, the drug accumulation was proportional 
to the extracellular concentration (data not shown). This 
might show that the influx of R-123 and other drugs was by 
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duced in MCF7/ADR cells in comparison with parental cells, 
they constantly expressed the MDR-1 gene and showed a 
differential chemosensitivity to adriamycin. These observa-
tions demonstrated that, even though the MDR-1 gene was 
expressed in MCF7/ADR cells, it was not related to the re-
sistant phenotype. Furthermore, the resistance of this cell was 
independent of the intracellular drug concentration. Further 
studies are needed to find the resistant mechanism not related 
with the intracellular drug concentrations and/or MDR-1 gene 
expression. 
Although the multidrug resistance mechanism of the 
present cells was not clear, it might be suggested that the 
MDR-1 gene/P-gp did not properly work due to the changes 
of the modulating factors. Possible mechanisms seemed to be 
related to the changes of intracellular calcium and cAMP 
levels [16] and other common mediators such as PKC, which 
modulated the function of P-gp [17,18]. Alteration of the glu-
£ « 
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Fig. 3. R-123 uptake and efflux in KB-3-1 (A), KB-Vl (A), MCF7 
(B), and MCF7/ADR cells (B). These cells were incubated with R-
123 (1 ug/ml). To determine the uptake, intracellular drug concen-
tration was determined every 10 min for 30 min. To determine the 
efflux, intracellular drug concentration was determined every 10 min 
after uptake R-123 for 30 min. The data here present the mean val-
ues ± standard deviation of three independent experiments which 
were done in six separate analyses. 
diffusion through the cytoplasmic membrane. Then it could be 
assumed that the difference of drug influx between KB-Vl and 
KB-3-1 was caused by the changes of cytoplasmic membrane. 
These results were also observed in PC-9/VCR. The low intra-
cellular drug concentration of resistant cells was mediated by 
a small drug uptake, which was reversed by ascorbic acid. PC-
9/VCR cells have been suggested to have an ascorbic acid-
sensitive drug uptake mechanism that differed from the P-
gp-mediated MDR mechanism [15]. KB-Vl cells exhibited 
similar mechanisms with PC-9/VCR in that both cell types 
expressed multidrug resistance phenotype by reducing drug 
uptake. 
Drug uptake and release rate of MCF7/ADR were the same 
as MCF7, suggesting that the intracellular drug concentration 
of both cells was the same. Also intracellular drug concentra-
tion was not changed by verapamil, a P-gp blocking agent. 
































Fig. 4. R-123 uptake and efflux in KB-3-1 (A), KB-Vl (A), MCF7 
(B), and MCF7/ADR cells (B). These cells were incubated with R-
123 (1 (ig/ml). To determine the uptake, intracellular drug concen-
tration was determined every 15 min for 60 min. To determine the 
efflux, intracellular drug concentration was determined at 15 min 
after uptake of R-123 for indicated periods from 15 to 60 min. The 
data present the mean values ± standard deviation of three inde-
pendent experiments which were done in six separate analyses. 
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Fig. 5. Effects of verapamil on the efflux of R-123 (A, B) and ADR (C, D) in MCF7 (A, C) and MCF7/ADR cells (B, D). Either R-123 (1 ug/ 
ml) or ADR (10 ug/ml) was administered to these cells. After washing verapamil was added at a final concentration of 5 itM for the indicated 
periods. To determine efflux, intracellular drug concentration was determined every 5 min. The data present the mean values of six separate 
analyses. 
tathione redox cycle could modify the intracellular concentra-
tion of calcium and cAMP, affecting the function of P-gp [16]. 
The expression and activity of PKC isoenzymes in the human 
breast cancer cell line (MCF-7-WT) and MDR subline (MCF-
7-MDR) were implicated in the regulation of the MDR phe-
notype through phosphorylation of P-gp [17]. The over-ex-
pression of PKC-a in an MCF-7 cell line already over-ex-
pressing P-gp has been shown to increase the MDR 
phenotype [18]. MRP might seem to contribute to the resist-
ance phenotype, because MRP was known to reduce the intra-
cellular drug concentration in the resistant cells (MCF7/VP) 
by MRP over-expression, in the absence of mdrl/P-glycopro-
tein expression and without any change in drug efflux [19]. 
The actual resistance mechanism of the present cells will be 
determined by examining these mechanisms. The relevance of 
drug uptake with intracellular calcium will be studied to find 
the resistant mechanism of KB-V1 and MCF7/ADR. 
From these results, it was clear that MDR-1 gene expres-
sion did not affect the kinetics of drug influx and efflux in the 
present cell system, indicating that the transcription rate of 
the MDR gene was not a critical factor in the acquisition of 
multidrug resistance. Even though these two cell systems show 
different mechanisms of resistance, these are unique models in 
which the over-expressed MDR gene does not participate in 
drug resistance. It may be possible that the MDR gene ex-
pression is related to resistance mechanisms in some cancer 
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Fig. 6. Quantification of intracellular ATP concentration. The con-
centration of ATP was quantified in KB-V1, KB-3-1, MCF7, and 
MCF7/ADR cells up to 30 min by the bioluminescence detection 
method. The data present the mean values of six separate analyses. 
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